A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer
Status:
Terminated
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
Drugs used in chemotherapy such as cisplatin and fluorouracil use different ways to stop
tumor cells from dividing so they stop growing or die. Oblimersen may increase the
effectiveness of chemotherapy by making tumor cells more sensitive to the drugs. This phase
I/II trial is studying the side effects and best dose of oblimersen when given with cisplatin
and fluorouracil and to see how well they work in treating patients with locally advanced,
recurrent, or metastatic cancer of the esophagus, gastroesophageal junction, or stomach.